Definium's LSD Pill Eases Anxiety in Phase 3 Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Definium Therapeutics announced Wednesday that its LSD therapy significantly reduced generalized anxiety disorder symptoms in a Phase 3 study, marking the company's first late-stage anxiety win.
- The trial enrolled 214 patients randomized to receive a single dose of DT120 — Definium's "proprietary, pharmaceutically optimized" LSD pill — or placebo.
- The anxiety results mark Definium's second major Phase 3 win in two months, following a late-stage success in major depression reported earlier.
- The GAD study is the first of two large Phase 3 trials Definium is running for its LSD-based anxiety program.
Why it matters: With back-to-back Phase 3 wins in two distinct psychiatric indications — anxiety and depression — Definium has now generated late-stage evidence for a single-dose, pharmaceutically optimized LSD formulation, a notable run for a psychedelic drug program and a different dosing paradigm than chronic daily psychiatric medications.
Ask SkimNews
